Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884

Clinical characteristics of coronavirus disease 2019 in China

Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246

A novel coronavirus from patients with pneumonia in China, 2019

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Gorbalenya, A. E., Baker, S. C., Baric, R. S., de Groot, R. J., Drosten, C., Gulyaeva, A. A., Haagmans, B. L., Lauber, C., Leontovich, A. M., Neuman, B. W., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0695-z · Cited by 8,745

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923

Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia

Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,677

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Hamming, I., Timens, W., Bulthuis, M., Lely, A., Navis, G., & van Goor, H. (2004) · The Journal of Pathology · doi:10.1002/path.1570 · Cited by 5,676

Clinical and immunological features of severe and moderate coronavirus disease 2019

Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750

Analysis of laboratory parameters in patients with COVID-19: Experiences from a pandemic hospital

Özdemir, S., Eroğlu, S. E., Algın, A., Akça, H. Ş., Özkan, A., Pala, E., Aydın, M., & Aksel, G. (2021) · The Annals of Clinical and Analytical Medicine · doi:10.4328/acam.20678 · Cited by 20

Persistence of T Cell and Antibody Responses to SARS-CoV-2 Up to 9 Months after Symptom Onset

Law, J. C., Girard, M., Chao, G. Y. C., Ward, L. A., Isho, B., Rathod, B., Colwill, K., Li, Z., Rini, J. M., Yue, F. Y., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100727 · Cited by 23

Acute kidney injury associated to COVID-19 leads to a strong unbalance of circulant immune mediators

Medeiros, T., Guimarães, G. M. C., Carvalho, F. R., Alves, L. S., Faustino, R. D. S., Campi‐Azevedo, A. C., Peruhype-Magalhães, V., Teixeira‐Carvalho, A., Gomes, M. D. S., do Amaral, L. R., et al. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155974 · Cited by 20

Age-dependent NK cell dysfunctions in severe COVID-19 patients

Fionda, C., Ruggeri, S., Sciumè, G., Laffranchi, M., Quinti, I., Milito, C., Palange, P., Menichini, I., Sozzani, S., Frati, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1039120 · Cited by 20

Functional changes in cytotoxic CD8+ T-cell cross-reactivity against the SARS-CoV-2 Omicron variant after mRNA vaccination

Nogimori, T., Suzuki, K., Masuta, Y., Yagoto, M., Ikeda, M., Katayama, Y., Washizaki, A., Kanda, H., Takada, M., Minami, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1081047 · Cited by 19

An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activity

Wing, P. A. C., Schmidt, N. M., Peters, R., Erdmann, M., Brown, R. L., Wang, H., Swadling, L., COVIDsortium Investigators, Newman, J., Thakur, N., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011323 · Cited by 23

Age-dependent acquisition of pathogenicity by SARS-CoV-2 Omicron BA.5

Imbiakha, B., Ezzatpour, S., Buchholz, D. W., Sahler, J., Ye, C., Olarte‐Castillo, X. A., Zou, A., Kwas, C. T., O’Hare, K., Choi, A., et al. (2023) · Science Advances · doi:10.1126/sciadv.adj1736 · Cited by 21

Measurement of IFN-γ and IL-2 for the assessment of the cellular immunity against SARS-CoV-2

Safont, G., Villar-Hernández, R., Smalchuk, D., Stojanović, Z., Marín, A., Lacoma, A., Pérez-Cano, C., López-Martínez, A., Molina-Moya, B., Solis, A. J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-51505-w · Cited by 21

TLR2/4 are novel activating receptors for SARS-CoV-2 spike protein on NK cells

Landolina, N., Ricci, B., Veneziani, I., Alicata, C., Mariotti, F. R., Pelosi, A., Quatrini, L., Mortari, E. P., Carsetti, R., Vacca, P., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1368946 · Cited by 20

An Overview of Nucleic Acid Testing for the Novel Coronavirus SARS-CoV-2

Wang, H., Li, G., Zhao, J., Li, Y., & Ai, Y. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.571709 · Cited by 20

SARS-CoV-2-Specific T Cell Responses in Patients with COVID-19 and Unexposed Individuals

Rha, M., Kim, A. R., & Shin, E. (2021) · Immune Network · doi:10.4110/in.2021.21.e2 · Cited by 20

Differential alterations in peripheral lymphocyte subsets in COVID-19 patients: upregulation of double-positive and double-negative T cells

Zahran, A. M., Zahran, Z. A. M., Mady, Y. H., Mahran, E. E. M. O., Rashad, A., Makboul, A., Nasif, K. A., Abdelmaksoud, A. A., & El‐Badawy, O. (2021) · Multidisciplinary Respiratory Medicine · doi:10.4081/mrm.2021.758 · Cited by 21

The Effect of Unconventional Cytokine Combinations on NK-Cell Responses to Viral Infection

Ochayon, D. E., & Waggoner, S. N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645850 · Cited by 20

Severe T cell hyporeactivity in ventilated COVID-19 patients correlates with prolonged virus persistence and poor outcomes

Renner, K., Schwittay, T., Chaabane, S., Gottschling, J., Müller, C., Tiefenböck, C., Salewski, J.-N., Winter, F., Buchtler, S., Balam, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23334-2 · Cited by 23

TREC/KREC Levels in Young COVID-19 Patients

Khadzhieva, M. B., Kalinina, E. V., Larin, S. S., Свиридова, Д. А., Gracheva, A. S., Chursinova, J., Stepanov, V. A., Редкин, И. В., Avdeikina, L. S., Rumyantsev, A. G., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11081486 · Cited by 19

Mast cells: Therapeutic targets for COVID ‐19 and beyond

Lam, H. Y., Tergaonkar, V., Kumar, A. P., & Ahn, K. S. (2021) · IUBMB Life · doi:10.1002/iub.2552 · Cited by 17

COVID‐19 Pandemic and Periodontal Practice: The Immunological, Clinical, and Economic Points of View

Darestani, M. N., Akbari, A. A., Yaghobee, S., Taheri, M., & Akbari, S. (2022) · BioMed Research International · doi:10.1155/2022/3918980 · Cited by 18

The deciphering of the immune cells and marker signature in COVID‐19 pathogenesis: An update

Jasim, S. A., Mahdi, R. S., Bokov, D. O., Najm, M. A. A., Sobirova, G. N., Bafoeva, Z. O., Taifi, A., Alkadir, O. K. A., Mustafa, Y. F., Mirzaei, R., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28000 · Cited by 21

Advances in Biomarkers for Diagnosis and Treatment of ARDS

Ge, R., Wang, F., & Peng, Z. (2023) · Diagnostics · doi:10.3390/diagnostics13213296 · Cited by 19

Demystifying Excess Immune Response in COVID-19 to Reposition an Orphan Drug for Down-Regulation of NF-κB: A Systematic Review

Peddapalli, A., Gehani, M., Kalle, A. M., Peddapalli, S. R., Peter, A. E., & Sharad, S. (2021) · Viruses · doi:10.3390/v13030378 · Cited by 19

Hemophagocytic histiocytosis in severe SARS‐CoV‐2 infection: A bone marrow study

Dandu, H. R., Yadav, G., Malhotra, H. S., Pandey, S., Sachu, R., & Dubey, K. (2021) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13619 · Cited by 19

Validation of Multi-epitope Peptides Encapsulated in PLGA Nanoparticles Against Influenza A Virus

Heng, W. T., Lim, H. X., Tan, K. O., & Poh, C. L. (2023) · Pharmaceutical Research · doi:10.1007/s11095-023-03540-x · Cited by 18

Next-generation treatments: Immunotherapy and advanced therapies for COVID-19

Romero, J. A. A., Chingaté-López, S. M., Camacho, B., Alméciga-Díaz, C. J., & Ramirez-Segura, C. A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26423 · Cited by 19

COVID-19: from immune response to clinical intervention

Guo, Z.-Y., Tang, Y., Zhang, Z.-B., Liu, J., Zhuang, Y., & Li, T. (2024) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbae015 · Cited by 18

Endothelial cell, myeloid, and adaptive immune responses in SARS‐CoV‐2 infection

Degauque, N., Haziot, A., Brouard, S., & Mooney, N. (2021) · The FASEB Journal · doi:10.1096/fj.202100024r · Cited by 14

An update on host immunity correlates and prospects of re-infection in COVID-19

Negi, N., Maurya, S. P., Singh, R., & Das, B. K. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.2019727 · Cited by 20

Obesity and metabolic dysfunction drive sex-associated differential disease profiles in hACE2-mice challenged with SARS-CoV-2

Lee, K. S., Russ, B. P., Wong, T. Y., Horspool, A. M., Winters, M. T., Barbier, M., Bevere, J. R., Martínez, I., Damron, F. H., & Cyphert, H. A. (2022) · iScience · doi:10.1016/j.isci.2022.105038 · Cited by 18

Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab

Salvati, L., Occhipinti, M., Gori, L., Ciani, L., Mazzoni, A., Maggi, L., Capone, M., Parronchi, P., Liotta, F., Miele, V., et al. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.10.009 · Cited by 17

High‑dose intravenous immunoglobulins as a therapeutic option in critical illness polyneuropathy accompanying SARS‑CoV‑2 infection: A case‑based review of the literature (Review)

Stoian, A., Bajkó, Z., Maier, S., Cioflinc, R. A., Grigorescu, B. L., Moțățăianu, A., Bărcuţean, L., Bălașa, R., & Stoian, M. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10616 · Cited by 18

Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection

Kumar, A., Sharma, A., Tirpude, N. V., Sharma, S., Padwad, Y. S., & Kumar, S. (2022) · Inflammopharmacology · doi:10.1007/s10787-021-00903-x · Cited by 18

Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider

Najm, A., Alunno, A., Mariette, X., Terrier, B., Marco, G. D., Emmel, J., Mason, L., McGonagle, D., & Machado, P. (2021) · RMD Open · doi:10.1136/rmdopen-2020-001549 · Cited by 17

Innate lymphoid cells (ILC) in SARS-CoV-2 infection

Kumar, A., Cao, W., Endrias, K., Kuchipudi, S. V., Mittal, S. K., & Sambhara, S. R. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101008 · Cited by 17

Genetics of COVID ‐19 and myalgic encephalomyelitis/chronic fatigue syndrome: a systematic review

Tziastoudi, M., Cholevas, C., Stefanidis, I., & Theoharides, T. C. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51631 · Cited by 19

Increased B‐cell activity with consumption of activated monocytes in severe COVID‐19 patients

Kos, I. A., Balensiefer, B., Lesan, V., Kaddu‐Mulindwa, D., Thurner, L., Christofyllakis, K., Bittenbring, J. T., Ahlgrimm, M., Seiffert, M., Wagenpfeil, S., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202049163 · Cited by 16

Neutrophilia, lymphopenia and myeloid dysfunction: a living review of the quantitative changes to innate and adaptive immune cells which define COVID-19 pathology

Codd, A. S., Hanna, S. J., Compeer, E. B., Richter, F. C., Pring, E. J., Gea-Mallorquí, E., Borsa, M., Moon, O. R., Scourfield, D. O., Ahern, D., et al. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab016 · Cited by 16

Data-Driven Analysis of COVID-19 Reveals Persistent Immune Abnormalities in Convalescent Severe Individuals

Lim, J., Puan, K. J., Wang, L. W., Teng, K. W. W., Loh, C. Y., Tan, K. P., Carissimo, G., Chan, Y., Poh, C. M., Lee, C. Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.710217 · Cited by 17

Alum/CpG Adjuvanted Inactivated COVID-19 Vaccine with Protective Efficacy against SARS-CoV-2 and Variants

Zhang, Y., Zheng, X., Sheng, W., Liang, H., Zhao, Y., Zhu, X., Yang, R., Zhang, Y., Dong, X., Li, W., et al. (2022) · Vaccines · doi:10.3390/vaccines10081208 · Cited by 16

In vivo inhibition of nuclear ACE2 translocation protects against SARS-CoV-2 replication and lung damage through epigenetic imprinting

Tu, W. J., Melino, M., Dunn, J., McCuaig, R., Bielefeldt‐Ohmann, H., Tsimbalyuk, S., Forwood, J. K., Ahuja, T., Vandermeide, J., Tan, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39341-4 · Cited by 16

Do COVID-19 Infections Result in a Different Form of Secondary Hemophagocytic Lymphohistiocytosis

Chu, R., van Eeden, C., Suresh, S., Sligl, W., Osman, M. S., & Tervaert, J. W. C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062967 · Cited by 15

Pathological Effects of SARS-CoV-2 Associated with Hematological Abnormalities

Shama, S., Mahmood, A., Mehmood, S., & Zhang, W. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45090453 · Cited by 18

SARS-CoV-2 and Plasma Hypercoagulability

Steadman, E., Fandaros, M., & Yin, W. (2021) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-021-00685-w · Cited by 15

Clinical Relevance of Elevated Soluble ST2, HSP27 and 20S Proteasome at Hospital Admission in Patients with COVID-19

Wendt, R. T., Lingitz, M., Laggner, M., Mildner, M., Traxler, D., Graf, A. C., Krotka, P., Moser, B., Höetzenecker, K., Kalbitz, S., et al. (2021) · Biology · doi:10.3390/biology10111186 · Cited by 15

Where do T cell subsets stand in SARS-CoV-2 infection: an update

Tarique, M., Suhail, M., Naz, H., Muhammad, N., Tabrez, S. S. M., Zughaibi, T. A., Abuzenadah, A. M., Hashem, A. M., Shankar, H., Saini, C., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.964265 · Cited by 16

Peptides Derived From S and N Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 Induce T Cell Responses: A Proof of Concept for T Cell Vaccines

Lee, Y., Hong, S., Park, H., Lee, H., Hwang, J.-Y., Kim, S. Y., Park, J. W., Choi, K.-S., Seong, J. K., Park, S., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.732450 · Cited by 14

The hyperinflammatory spectrum: from defects in cytotoxicity to cytokine control

Planas, R., Felber, M., Vavassori, S., & Schmid, J. P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1163316 · Cited by 14

Inflammatory Progression in Patients Undergoing Extracorporeal Membrane Oxygenation

Yao, Y., Kang, H.-Y., Cheng, Y., Su, X., & Wang, B. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230619102723 · Cited by 14

Role of the Immune Microenvironment in SARS-CoV-2 Infection

Ye, C.-H., Hsu, W., Peng, G.-R., Yu, W.-C., Lin, W., Hu, S., & Yu, S. (2021) · Cell Transplantation · doi:10.1177/09636897211010632 · Cited by 15

From COVID-19 to Sarcoidosis: How Similar Are These Two Diseases?

Zhao, M., Tian, C., Cong, S., Di, X., & Wang, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.877303 · Cited by 14

Molecular mechanisms involved in pathogenicity of SARS-CoV-2: Immune evasion and implications for therapeutic strategies

Latifi-Pupovci, H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113368 · Cited by 16

Gastrointestinal Microenvironment and the Gut-Lung Axis in the Immune Responses of Severe COVID-19

Yang, Y. K., Huang, W., Fan, Y., & Chen, G. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.647508 · Cited by 15

Jinhua Qinggan granule, a Chinese herbal medicine against COVID‑19, induces rapid changes in the neutrophil/lymphocyte ratio and plasma levels of IL‑6 and IFN‑γ: An open‑label, single‑arm pilot study

Kageyama, Y., Aida, K., Kawauchi, K., Morimoto, M., Ebisui, T., Akiyama, T., & Nakamura, T. (2021) · World Academy of Sciences Journal · doi:10.3892/wasj.2021.137 · Cited by 15

Platelets modulate CD4+ T‐cell function in COVID‐19 through a PD‐L1 dependent mechanism

Paletta, A. L., García, F. D. D., Varese, A., Díaz, F. A. E., García, J. L., Cisneros, J. C., Ludueña, G., Mazzitelli, I. G., Pisarevsky, A. A., Cabrerizo, G., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18062 · Cited by 14

Longitudinal Characteristics of T Cell Responses in Asymptomatic SARS-CoV-2 Infection

Yang, J., Zhang, E., Zhong, M., Yang, Q., Hong, K., Shu, T., Zhou, D., Xiang, J., Xia, J., Zhou, X., et al. (2020) · Virologica Sinica · doi:10.1007/s12250-020-00277-4 · Cited by 13

New Discovery of Myeloid-Derived Suppressor Cell’s Tale on Viral Infection and COVID-19

Park, S., Nam, D., Seong, H. C., & Hahn, Y. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.842535 · Cited by 14

NK cell dysfunction is linked with disease severity in SARS‐CoV‐2 patients

Asl, K. D., Mazloumi, Z., Majidi, G., Kalarestaghi, H., Sabetkam, S., & Rafat, A. (2022) · Cell Biochemistry and Function · doi:10.1002/cbf.3725 · Cited by 13

Are NKT cells a useful predictor of COVID-19 severity?

Koay, H., Gherardin, N. A., Nguyen, T. H. O., Zhang, W., Habel, J. R., Seneviratna, R., James, F., Holmes, N. E., Smibert, O. C., Gordon, C. L., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.01.005 · Cited by 13

IL4I1 binds to TMPRSS13 and competes with SARS-CoV-2 spike

Gatineau, J., Nidercorne, C., Dupont, A., Puiffe, M., Cohen, J. L., Molinier‐Frenkel, V., Niedergang, F., & Castellano, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.982839 · Cited by 12

Deciphering suppressive effects of Lianhua Qingwen Capsule on COVID-19 and synergistic effects of its major botanical drug pairs

Yuanyuan, C. H. E. N., Zhang, C., Wang, N., & Feng, Y. (2023) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(23)60455-8 · Cited by 13

Systems immunology integrates the complex endotypes of recessive dystrophic epidermolysis bullosa

Hirt, N., Manchon, E., Chen, Q., Delaroque, C., Corneau, A., Hémon, P., Saker-Delye, S., Bataille, P., Bouaziz, J., Bourrat, E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55934-7 · Cited by 14

Immunouniverse of SARS-CoV-2

Jiménez, D., & Arias, M. T. (2022) · Immunological Medicine · doi:10.1080/25785826.2022.2066251 · Cited by 12

Histopathological examination of the placenta after delivery in pregnant women with COVID-19

Taş, F., Erdemci, F., Aşir, F., Maraşlı, M., & Devecí, E. (2022) · Journal of Health Sciences and Medicine · doi:10.32322/jhsm.1100731 · Cited by 12

SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise

Duerr, R., Crosse, K. M., Valero-Jimenez, A. M., & Dittmann, M. (2021) · Microorganisms · doi:10.3390/microorganisms9071389 · Cited by 12

Profound CD8 T cell responses towards the SARS-CoV-2 ORF1ab in COVID-19 patientsPreprint

Gangaev, A., Ketelaars, S. L. C., Patiwael, S., Dopler, A., Isaeva, O. I., Hoefakker, K., Biasi, S. D., Mussini, C., Guaraldi, G., Girardis, M., et al. (2020) · doi:10.21203/rs.3.rs-33197/v1 · Cited by 12

Adaptive immune responses to SARS-CoV-2

Forthal, D. N. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.009 · Cited by 11

Influence of Galectin-9 Treatment on the Phenotype and Function of NK-92MI Cells in the Presence of Different Serum Supplements

Meggyes, M., Nagy, D. U., Balassa, T., Gödöny, K., Péterfalvi, Á., Szereday, L., & Polgár, B. (2021) · Biomolecules · doi:10.3390/biom11081066 · Cited by 11

COVID-19 infection as a new risk factor for penile Mondor disease

Balawender, K., Pliszka, A., Surowiec, A., & Rajda, S. (2022) · BMC Urology · doi:10.1186/s12894-022-01002-x · Cited by 11

Cellular heterogeneity in disease severity and clinical outcome: Granular understanding of immune response is key

Khare, K., & Pandey, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.973070 · Cited by 15

Immunological Characteristics of Non-Intensive Care Hospitalized COVID-19 Patients: A Preliminary Report

Corrao, S., Gervasi, F., Bernardo, F. D., Natoli, G., Raspanti, M., Catalano, N., & Argano, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040849 · Cited by 11

Anakinra and Intravenous IgG versus Tocilizumab in the Treatment of COVID-19 PneumoniaPreprint

Zantah, M., Castillo, E. D., Gangemi, A. J., Patel, M., Chowdhury, J. M., Verga, S. R., Abramian, O., Zheng, M., Lu, K., Lau, A. C. W., et al. (2020) · medRxiv · doi:10.1101/2020.09.11.20192401 · Cited by 11

Serum Adiponectin Predicts COVID-19 Severity

Pavel, V., Räth, U., Schmid, S. A., Krautbauer, S., Keller, D., Amend, P., Müller, M., Mester, P., & Buechler, C. (2024) · Biomedicines · doi:10.3390/biomedicines12051043 · Cited by 10

First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia

Omar Valenzuela, L., Ibañez, S., Poli, M. C., Roessler, P., Aylwin, M., Gigia Roizen, G., Iruretagoyena, M., Agar, V., Donoso, J., Fierro, M., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.596916 · Cited by 12

Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic

Weber, M. S., Nicholas, J. A., & Yeaman, M. R. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001067 · Cited by 12

The Dynamic Immunological Parameter Landscape in Coronavirus Disease 2019 Patients With Different Outcomes

Tang, G., Huang, M., Luo, Y., Liu, W. Y., Lin, Q., Mao, L., Wu, S., Xiong, Z., Hou, H., Sun, Z., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.697622 · Cited by 11

Antibody profiles in COVID ‐19 convalescent plasma prepared with amotosalen/ UVA pathogen reduction treatment

Bagri, A., de Assis, R. R., Tsai, C., Simmons, G., Mei, Z. W., von Goetz, M., Gatmaitan, M., Stone, M., Germanio, C. D., Martinelli, R., et al. (2022) · Transfusion · doi:10.1111/trf.16819 · Cited by 8

Prognostic peripheral blood biomarkers at ICU admission predict COVID-19 clinical outcomes

Messing, M., Sekhon, M. S., Hughes, M. R., Stukas, S. K., Hoiland, R. L., Cooper, J. G., Ahmed, N., Hamer, M. S., Li, Y., Shin, S. B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1010216 · Cited by 11

SARS-CoV-2 NSP5 antagonizes MHC II expression by subverting histone deacetylase 2

Taefehshokr, N., Lac, A., Vrieze, A. M., Dickson, B. H., Guo, P. N., Jung, C., Blythe, E. N., Fink, C., Aktar, A., Dikeakos, J. D., et al. (2024) · Journal of Cell Science · doi:10.1242/jcs.262172 · Cited by 16

What we know and still ignore on COVID‐19 immune pathogenesis and a proposal based on the experience of allergic disorders

Maggi, E., Azzarone, B. G., Canonica, G. W., & Moretta, L. (2021) · Allergy · doi:10.1111/all.15112 · Cited by 9

Thrombocytopenia in COVID‑19 and vaccine‑induced thrombotic thrombocytopenia

Geronikolou, S. A., Takan, I., Pavlopoulou, A., Mantzourani, M., & Chrousos, G. P. (2022) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2022.5090 · Cited by 10

Long‐term SARS‐CoV‐2‐specific and cross‐reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology

Laurén, I., Havervall, S., Ng, H., Lord, M., Pettke, A., Greilert‐Norin, N., Gabrielsson, L., Chourlia, A., Amoêdo‐Leite, C., Josyula, V. S., et al. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.595 · Cited by 9

SARS-CoV-2 and Immunity: Natural Infection Compared with Vaccination

Vespa, S., Simeone, P., Catitti, G., Buca, D., Bellis, D. D., Pierdomenico, L., Pieragostino, D., Cicalini, I., Boccio, P. D., Natale, L., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168982 · Cited by 10

Hemophagocytic Syndrome and COVID-19: A Comprehensive Review

Fadlallah, M. M., Salman, S. M., Fadlallah, M. M., & Rahal, H. (2023) · Cureus · doi:10.7759/cureus.36140 · Cited by 11

Higher proinflammatory responses possibly contributing to suppressed cytotoxicity in patients with COVID-19 associated mucormycosis

Shete, A., Deshpande, S., Sawant, J., Warthe, N., Thakar, M. R., Madkaikar, M. R., Pradhan, V., Rao, P., Rohatgi, S. J., Mukherjee, A., et al. (2023) · Immunobiology · doi:10.1016/j.imbio.2023.152384 · Cited by 10

Chronic inflammation deters natural killer cell fitness and cytotoxicity in myeloid leukemia

Kuznetsova, V., Krishnan, V., da Costa, A. B. B., Ren, X., Ricketts, T. D., Patel, S. B., Connelly, A. N., Goel, P., Knapp, J., Franceski, A. M., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014592 · Cited by 9

The identification of a SARs-CoV2 S2 protein derived peptide with super-antigen-like stimulatory properties on T-cells

Tu, T. H., Bennani, F. E., Masroori, N., Liu, C., Nemati, A., Rozza, N., Grunbaum, A., Kremer, R. B., Milhalcioiu, C., Roy, D., et al. (2025) · Communications Biology · doi:10.1038/s42003-024-07350-8 · Cited by 9

Role of IL-6–IL-27 Complex in Host Antiviral Immune Response

Zuo, Q., Cheng, Z., Zhang, G., Xia, Y., Xu, G., Cao, W., Yang, X., Fu, Y.-D., He, R., Fang, P., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100179 · Cited by 10

Expression of NKG2A inhibitory receptor on cytotoxic lymphocytes as an indicator of severity in Corona Virus Disease 2019 (COVID-19) patients

Yasin, M. M., Shehata, I. H., Elsheikh, N. G., & Elsayed, M. (2021) · Egyptian journal of Immunology · doi:10.55133/eji.280116 · Cited by 9

In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection

Romano, A., Parrinello, N. L., Barchitta, M., Manuele, R., Puglisi, F., Maugeri, A., Barbato, A., Triolo, A. M., Giallongo, C., Tibullo, D., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-11157-0 · Cited by 10

Immune Cells Profiles In The Peripheral Blood Of Patients With Moderate To Severe COVID-19 And Healthy Subjects With and Without Vaccination With The Pfizer-BioNTech mRNA Vaccine

Al‐Attiyah, R., Safar, H. A., Botras, L., Botras, M., Al-Kandari, F., Chehadeh, W., & Mustafa, A. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.851765 · Cited by 9

SARS-CoV-2 and Endothelial Cells: Vascular Changes, Intussusceptive Microvascular Growth and Novel Therapeutic Windows

Solimando, A. G., Marziliano, D., & Ribatti, D. (2022) · Biomedicines · doi:10.3390/biomedicines10092242 · Cited by 9

Prognostic Nutritional Index and Crp, Age, Platelet Count, Albumin Level Score in Predicting Mortality and Intensive Care Unit Admission for Covid-19

Bayram, M., Yıldırım, Ö., ÖZMEN, R. S., Soylu, B., Dündar, A., Köksal, A. R., Ekinci, İ., Akarsu, M., & Tabak, Ö. (2021) · Biomarkers in Medicine · doi:10.2217/bmm-2021-0337 · Cited by 9

Severe Type of COVID-19: Pathogenesis, Warning Indicators and Treatment

Shi, K., Liu, Y., Zhang, Q., Ran, C., Hou, J., Zhang, Y., & Wang, X. (2021) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-021-3313-x · Cited by 10

Ad26.COV2.S prevents upregulation of SARS-CoV-2 induced pathways of inflammation and thrombosis in hamsters and rhesus macaques

Aïd, M., Vidal, S. J., Piedra-Mora, C., Ducat, S., Chan, C. N., Bondoc, S., Colarusso, A., Starke, C. E., Nekorchuk, M. D., Busman‐Sahay, K., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1009990 · Cited by 10

What Inhibits Natural Killers’ Performance in Tumour

Papak, I., Chruściel, E., Dziubek, K., Kurkowiak, M., Urban‐Wójciuk, Z., Marjański, T., Rzyman, W., & Marek-Trzonkowska, N. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137030 · Cited by 9

Lymphocyte Population Changes at Two Time Points during the Acute Period of COVID-19 Infection

Scalia, G., Raia, M., Gelzo, M., Cacciapuoti, S., Rosa, A. D., Pinchera, B., Scotto, R., Tripodi, L., Mormile, M., Fabbrocini, G., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154306 · Cited by 9

Current Developments in the Preclinical and Clinical use of Natural Killer T cells

Kratzmeier, C., Singh, S. A., Asiedu, E. B., & Webb, T. J. (2022) · BioDrugs · doi:10.1007/s40259-022-00572-4 · Cited by 9

Implications of Laboratory Tests in Disease Grading and Death Risk Stratification of COVID-19: A Retrospective Study in Wuhan, China

Bai, Y., Wang, E., Zhao, S., Li, J., Zhu, Y., Zhang, Y., Cao, L., Liu, H., Dong, Y., Wang, F., et al. (2020) · Frontiers in Medicine · doi:10.2139/ssrn.3722066 · Cited by 9

Immune System Disequilibrium—Neutrophils, Their Extracellular Traps, and COVID-19-Induced Sepsis

Keane, C., Coalter, M., & Martín‐Loeches, I. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.711397 · Cited by 9

Neutrophil-Lymphocyte Ratio Predicting Case Severity in SARS-CoV-2 Infection: A Review

Agarwal, S. (2022) · Cureus · doi:10.7759/cureus.29760 · Cited by 9

Differential Gene Expression of SARS-CoV-2 Positive Bronchoalveolar Lavages: A Case Series

Haslbauer, J. D., Prince, S. S., Stalder, A. K., Matter, M. S., Zinner, C., Jahn, K., Obermann, E. C., Hanke, J., Leuzinger, K., Hirsch, H. H., et al. (2023) · Pathobiology · doi:10.1159/000532057 · Cited by 8

Elevated levels of cell-free NKG2D-ligands modulate NKG2D surface expression and compromise NK cell function in severe COVID-19 disease

Fernández‐Soto, D., García-Jiménez, Á. F., Casasnovas, J. M., Valés‐Gómez, M., & Reyburn, H. T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1273942 · Cited by 8

Severe COVID-19 patients display hyper-activated NK cells and NK cell-platelet aggregates

Malengier‐Devlies, B., Filtjens, J., Ahmadzadeh, K., Boeckx, B., Vandenhaute, J., Visscher, A. D., Bernaerts, E., Mitera, T., Jacobs, C., Vanderbeke, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.861251 · Cited by 47

Immunological and inflammatory profiles during acute and convalescent phases of severe/ critically ill COVID-19 patients

Chen, Q., Yu, B., Yang, Y., Huang, J., Liang, Y., Zhou, J., Li, L., Peng, X., Cheng, B., & Lin, Y. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107685 · Cited by 29

Coordinated Loss and Acquisition of NK Cell Surface Markers Accompanied by Generalized Cytokine Dysregulation in COVID-19

Ustiuzhanina, M. O., Vavilova, J. D., Boyko, A. A., Streltsova, M. A., Kust, S. A., Kanevskiy, L. M., Sapozhnikov, A. M., Iskhakov, R. N., Gubernatorova, E. O., Drutskaya, M. S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031996 · Cited by 20

Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19

Osman, M. S., Faridi, R. M., Sligl, W., Shabani‐Rad, M., Dharmani‐Khan, P., Parker, A., Kalra, A., Tripathi, M. B., Storek, J., Tervaert, J. W. C., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002650 · Cited by 131

Comparison of T Lymphocyte Subsets and Natural Killer Lymphocytes in Moderate Versus Severe COVID-19 Patients

Gabr, H. M., Abdel_Aal, A. A., Bastawy, S., Fateen, M., Dayem, O. A. E., Youssef, E. A., Afifi, R. M., & Kamal, M. (2023) · Viral Immunology · doi:10.1089/vim.2022.0125 · Cited by 3